What we do

Symphogen is a Center of Excellence for Antibody discovery and development site with clinical-stage antibody oncology-focused programs and a differentiated product pipeline. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations.

Our  strategy is to develop innovative therapies for the treatment of cancer and other significant diseases using our unique mAb platform.

Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb products candidates. We have a number of  pre-clinical and clinical product candidates with  the potential to provide meaningful treatment options for cancer patients that are not currently available.

Read more about our mAb mixtures